Targeting Hepatocyte Growth Factor with Protease Inhibitors in Lung Cancer

April 9th, 2018 – Jim Janetka, PhD, Associate Professor of Biochemistry and Molecular Biophysics, and Co-Founder of ProteXase Therapeutics, Inc., along with Lidija Klampfer, PhD, Co-Founder and Chief Scientific Officer of ProteXase Therapeutics, Inc., received a one-year SBIR grant award from the National Cancer Institute for their research entitled “Targeting Hepatocyte Growth Factor with Protease Inhibitors in Lung Cancer”.